Skip to main content

Table 5 Relationship between splitting and amplification of 11q13.3-q13.4 and clinical features of primary ESCC tumors

From: Characterization of genetic rearrangements in esophageal squamous carcinoma cell lines by a combination of M-FISH and array-CGH: further confirmation of some split genomic regions in primary tumors

Clinical features

Splitting

Amplification

 

Frequency

P value

Frequency

P value

Gender

 Male

47.2% (50/106)

0.089 a

86.2% (94/109)

1.000 a

 Female

28.6% (8/28)

 

89.3% (25/28)

 

Age

 < 60

47.8% (33/69)

0.274

87.1% (61/70)

1.000 a

 ≥ 60

38.5% (25/65)

 

86.6% (58/67)

 

Tumor size

 T1, T2

50.0% (10/20)

0.511

85.0% (17/20)

0.728 a

 T3, T4

42.1% (48/114)

 

87.2% (102/117)

 

Lymph node metastasis

 N0

30.2% (19/63)

0.004

79.4% (50/63)

0.022 a

 N1

54.9% (39/71)

 

93.2% (69/74)

 

Stage

 I, IIa

29.3% (17/58)

0.004

79.3% (46/58)

0.039 a

 IIb, III, IV

53.9% (41/76)

 

92.4% (73/79)

 

Differentiation

 G1

40.7% (11/27)

0.762 b

85.2% (23/27)

0.118 b

 G2

41.7% (30/72)

 

91.9% (68/74)

 

 G3

48.6% (17/35)

 

77.8% (28/36)

 
  1. a Fisher’s test.
  2. b Kruskal–Wallis test.
  3. The P value which is not labeled with “a” or “b” is assessed by χ2 test.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us